143 related articles for article (PubMed ID: 38423047)
1. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D;
Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
3. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
Siva S; Ali M; Correa RJM; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; McLaughlin M; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Grubb W; Hannan R; Staehler M; Warner A; Louie AV
Lancet Oncol; 2022 Dec; 23(12):1508-1516. PubMed ID: 36400098
[TBL] [Abstract][Full Text] [Related]
4. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.
Siva S; Chesson B; Bressel M; Pryor D; Higgs B; Reynolds HM; Hardcastle N; Montgomery R; Vanneste B; Khoo V; Ruben J; Lau E; Hofman MS; De Abreu Lourenco R; Sridharan S; Brook NR; Martin J; Lawrentschuk N; Kron T; Foroudi F
BMC Cancer; 2018 Oct; 18(1):1030. PubMed ID: 30352550
[TBL] [Abstract][Full Text] [Related]
5. A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.
Correa RJM; Ahmad B; Warner A; Johnson C; MacKenzie MJ; Pautler SE; Bauman GS; Rodrigues GB; Louie AV
Radiat Oncol; 2018 Mar; 13(1):47. PubMed ID: 29558966
[TBL] [Abstract][Full Text] [Related]
6. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
Hannan R; McLaughlin MF; Pop LM; Pedrosa I; Kapur P; Garant A; Ahn C; Christie A; Zhu J; Wang T; Robles L; Durakoglugil D; Woldu S; Margulis V; Gahan J; Brugarolas J; Timmerman R; Cadeddu J
Eur Urol; 2023 Sep; 84(3):275-286. PubMed ID: 36898872
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK).
Siva S; Correa RJM; Warner A; Staehler M; Ellis RJ; Ponsky L; Kaplan ID; Mahadevan A; Chu W; Gandhidasan S; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Louie AV
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):941-949. PubMed ID: 32562838
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
Chang JY; Mehran RJ; Feng L; Verma V; Liao Z; Welsh JW; Lin SH; O'Reilly MS; Jeter MD; Balter PA; McRae SE; Berry D; Heymach JV; Roth JA;
Lancet Oncol; 2021 Oct; 22(10):1448-1457. PubMed ID: 34529930
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial.
Siva S; Pham D; Kron T; Bressel M; Lam J; Tan TH; Chesson B; Shaw M; Chander S; Gill S; Brook NR; Lawrentschuk N; Murphy DG; Foroudi F
BJU Int; 2017 Nov; 120(5):623-630. PubMed ID: 28188682
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
Palma DA; Olson R; Harrow S; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP; Schellenberg D; Ahmad B; Griffioen G; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Bauman GS; Warner A; Senan S
Lancet; 2019 May; 393(10185):2051-2058. PubMed ID: 30982687
[TBL] [Abstract][Full Text] [Related]
12. MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial.
Timmer FEF; Geboers B; Ruarus AH; Vroomen LGPH; Schouten EAC; van der Lei S; Vos DJW; Dijkstra M; Schulz HH; Bakker J; van den Bemd BAT; van den Tol PM; Puijk RS; Lissenberg-Witte BI; de Gruijl TD; de Vries JJJ; Lagerwaard FJ; Scheffer HJ; Bruynzeel AME; Meijerink MR
Lancet Gastroenterol Hepatol; 2024 May; 9(5):448-459. PubMed ID: 38513683
[TBL] [Abstract][Full Text] [Related]
13. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C
BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979
[TBL] [Abstract][Full Text] [Related]
14. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.
Tang C; Msaouel P; Hara K; Choi H; Le V; Shah AY; Wang J; Jonasch E; Choi S; Nguyen QN; Das P; Prajapati S; Yu Z; Khan K; Powell S; Murthy R; Sircar K; Tannir NM
Lancet Oncol; 2021 Dec; 22(12):1732-1739. PubMed ID: 34717797
[TBL] [Abstract][Full Text] [Related]
15. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
Siva S; Louie AV; Warner A; Muacevic A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh B; Correa RJ; Lo SS; Staehler M
Cancer; 2018 Mar; 124(5):934-942. PubMed ID: 29266183
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.
Chang JY; Senan S; Paul MA; Mehran RJ; Louie AV; Balter P; Groen HJ; McRae SE; Widder J; Feng L; van den Borne BE; Munsell MF; Hurkmans C; Berry DA; van Werkhoven E; Kresl JJ; Dingemans AM; Dawood O; Haasbeek CJ; Carpenter LS; De Jaeger K; Komaki R; Slotman BJ; Smit EF; Roth JA
Lancet Oncol; 2015 Jun; 16(6):630-7. PubMed ID: 25981812
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial.
Sahgal A; Myrehaug SD; Siva S; Masucci GL; Maralani PJ; Brundage M; Butler J; Chow E; Fehlings MG; Foote M; Gabos Z; Greenspoon J; Kerba M; Lee Y; Liu M; Liu SK; Thibault I; Wong RK; Hum M; Ding K; Parulekar WR;
Lancet Oncol; 2021 Jul; 22(7):1023-1033. PubMed ID: 34126044
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
Chang JY; Lin SH; Dong W; Liao Z; Gandhi SJ; Gay CM; Zhang J; Chun SG; Elamin YY; Fossella FV; Blumenschein G; Cascone T; Le X; Pozadzides JV; Tsao A; Verma V; Welsh JW; Chen AB; Altan M; Mehran RJ; Vaporciyan AA; Swisher SG; Balter PA; Fujimoto J; Wistuba II; Feng L; Lee JJ; Heymach JV
Lancet; 2023 Sep; 402(10405):871-881. PubMed ID: 37478883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
